We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Seattle Genetics (SGEN)
An SI Board Since November 2000
Posts SubjectMarks Bans
161 32 0
Emcee:  keokalani'nui Type:  Unmoderated
S-1 filed 11/20/00. JP Morgan, CIBC, BoA.

We discover and develop monoclonal antibody, or mAb, based drugs to treat cancer and related diseases. Using our mAb-based technologies and our expertise in cancer, we have assembled a portfolio of drug candidates targeted to many types of human cancers. We utilize our mAb-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. We are currently testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers. SGN-15 is in three phase II clinical trials in combination with the chemotherapy drug Taxotere. SGN-10 is in two phase I clinical trials, one as a single agent and the other in combination with Taxotere. We have five preclinical product candidates being developed to treat patients with solid tumors, melanoma or hematologic malignancies. One of our preclinical product candidates, SGN-14, is being developed by Genentech pursuant to a license agreement. In addition to providing us with the means to discover and develop mAb-based product candidates ourselves, our technologies allow us to partner with other companies also developing mAbs.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted Does not appears to me as "transformative" first lMiljenko Zuanic-6/26/2017
160Now that vadast is out, there is no near term reason to own SGEN, regardless thMiljenko Zuanic-6/19/2017
159Wow, whom can you trust this days? >Thirty suitors were apparently interestedMiljenko Zuanic-3/9/2017
158It is not clear how serious are VOD events, but they are to be concerned about, Miljenko Zuanic-3/6/2017
157The Q is not IF, it is WHEN (10K, from risk factors): " Our commitment of rMiljenko Zuanic-2/21/2017
156and concern opposite view: Zuanic-2/10/2017
155From today IMMU deal, strange option ( Zuanic-2/10/2017
154I am thinking seriously to close my SGEN position. Cley is hiding behind FDA wheMiljenko Zuanic-2/9/2017
153Beginning of the end for CD33A, or...???? Seattle Genetics, Miljenko Zuanic-12/27/2016
152Adcetris; looks like true synergistic activity with Opdivo for CHL: investor.seMiljenko Zuanic-12/5/2016
15133A should perform better as mono-therapy than (SNSS) vosaroxin-cyta combinationMiljenko Zuanic-12/5/2016
150<Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD3Miljenko Zuanic-12/5/2016
149(7+3) + CD33 in frontline AML for younger patients: Of 42 patients evaluable fMiljenko Zuanic-12/3/2016
148They discontinue Adcetris for front liner DCBCL (CD30 positive without vincristiMiljenko Zuanic-12/3/2016
147Lately, I was bit optimistic (more than regularly for bio-biologic) for SGEN, moMiljenko Zuanic-12/2/2016
146None posted here for 4 years.... Well, something is ongoing and any bit help! fMiljenko Zuanic-11/10/2016
145Seattle Genetics: Positive Read-Through From Roche's Investor Day A Seeking tnsaf-9/12/2012
144Seattle Genetics Inc. to discuss the ODAC Recommendations - Conference call Fri,tnsaf-7/15/2011
143And from Bloomberg: News doesn't get much better than this. Sea Otter-12/6/2010
142Remission rate 34 pct for Seattle Genetics drug <i>Sun Dec 5, 2010 8:00amSteve Lokness-12/5/2010
141ASG-5ME infused into first patient: =========================Sea Otter-9/30/2010
140BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seattle Genetics, Inc. (nigel bates-9/27/2010
139Seattle Genetics Announces Phase IIb Trial of Lintuzumab BOTHELL, Wash., Sep 13,mopgcw-9/13/2010
138BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Seattnigel bates-12/15/2009
137SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN - News) today repnigel bates-12/11/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):